Argireline vs Orforglipron
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Argireline
Argireline (Acetyl Hexapeptide-3) is a widely-used cosmetic peptide that reduces wrinkle depth by inhibiting neurotransmitter release. One of the first 'Botox-like' peptides developed for topical use.
Full details →Orforglipron
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (which is a peptide requiring special formulation), orforglipron is a small molecule — the first of a new class of oral GLP-1 drugs that can be taken without fasting restrictions. It is in Phase 3 trials for obesity and type 2 diabetes, with an FDA decision expected in 2026. Projected to reach $16 billion in annual sales by 2031.
Full details →Side-by-Side Comparison
| Aspect | Argireline | Orforglipron |
|---|---|---|
| Dose Range | 500 mcg–1 mg | 12 mg–45 mg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 4–8 weeks | — |
| Route | topical | oral |
| Mechanism | Inhibits the formation of the SNARE complex required for neurotransmitter release, reducing the intensity of muscle contractions that cause expression lines. | Orforglipron is a small-molecule agonist that binds and activates the GLP-1 receptor through the same signaling cascade as peptide GLP-1 agonists (cAMP elevation, insulin secretion, appetite suppression) but with a fundamentally different molecular structure. Being a non-peptide, it does not require protection from enzymatic degradation (no fatty acid conjugation needed), can be absorbed without special formulation, and has no fasting restrictions for administration. Once-daily oral dosing with a half-life of ~25-65 hours. |
| Typical Dosage | Topical: 5-10% concentration in serums, applied twice daily. Higher concentrations used in professional treatments. | Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established. |
| Administration | Topical application to clean skin. Most effective on expression lines (forehead, crow's feet). Consistent use required for visible results. | Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available. |
| Side Effects | Generally very well-tolerated. Occasional mild irritation or dryness. No systemic absorption at cosmetic doses. | Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%. |
| Best For |
Key Differences
Unique to Argireline:
Unique to Orforglipron:
Key Studies
Argireline
- Effects of Botulinum Toxin Type A and Argireline on Dermal Collagen Remodeling and Skin Biology in a Flap Model.
Aesthetic plastic surgery, 2026
- Influence of the modification of the cosmetic peptide Argireline on the affinity toward copper(II) ions.
Journal of peptide science : an official publication of the European Peptide Society, 2024
- Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia(®) Complexion Analysis camera system for objective skin analysis.
GMS Interdisciplinary plastic and reconstructive surgery DGPW, 2023
Orforglipron
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Lancet (London, England), 2026
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Nature medicine, 2026
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
JAMA, 2026
Ready to Learn More?
Looking for trusted sources?